Payment overview · 2025
General Payments
$2,097.49
119 reported records · 24 companies
Healthcare provider profile · identity verified
Brian L Smith, DO
Allopathic & Osteopathic Physicians|Family Medicine · NEOSHO, MO · NPI 1619926250
Verified facts
What the public records show
CMS Open Payments records show Brian L Smith, DO received $2,097.49 in general payments during 2025 across 119 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $361.65 | 17.2% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $336.52 | 16.0% | 26 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $174.19 | 8.3% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $129.15 | 6.2% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $122.35 | 5.8% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $117.64 | 5.6% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $116.89 | 5.6% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $84.37 | 4.0% | 4 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $83.50 | 4.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.64 | 3.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.21 | 3.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $62.35 | 3.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $59.85 | 2.9% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $57.67 | 2.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.97 | 2.4% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.40 | 2.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.72 | 1.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.63 | 1.4% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $20.14 | 1.0% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.73 | 0.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.54 | 0.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $16.54 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.34 | 0.8% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $13.50 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,097.49 | 119 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $317.06 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $188.02 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $172.57 | 17 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $151.34 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $144.22 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $126.59 | 11 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $117.64 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $116.89 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $111.42 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $111.42 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $109.93 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.10 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $86.65 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $84.37 | 5 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $83.50 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $66.21 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $62.35 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $57.67 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.40 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.12 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.72 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $29.63 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.75 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 17 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 133 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 68 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 145 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 134 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
134 | 19 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
136 | 30 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 38 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 721 | 181 |
| Lisinopril | Lisinopril | 590 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 556 | 127 |
| Gabapentin | Gabapentin | 533 | 133 |
| Tramadol Hcl | Tramadol Hcl | 516 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 497 | 120 |
| Losartan Potassium | Losartan Potassium | 451 | 105 |
| Omeprazole | Omeprazole | 446 | 123 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 445 | 89 |
| Metformin Hcl Er | Metformin Hcl | 322 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 298 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 78 |
| Trazodone Hcl | Trazodone Hcl | 294 | 73 |
| Potassium Chloride | Potassium Chloride | 277 | 68 |
| Furosemide | Furosemide | 273 | 70 |
| Sertraline Hcl | Sertraline Hcl | 248 | 64 |
| Metformin Hcl | Metformin Hcl | 236 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 218 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 209 | 58 |
| Meloxicam | Meloxicam | 205 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 204 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 204 | 48 |
| Montelukast Sodium | Montelukast Sodium | 199 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 180 | 24 |
| Pregabalin | Pregabalin | 178 | 26 |
| Carvedilol | Carvedilol | 173 | 45 |
| Clonazepam | Clonazepam | 167 | 22 |
| Famotidine | Famotidine | 162 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 159 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 159 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 149 | 33 |
| Jardiance | Empagliflozin | 145 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 145 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 32 |
| Ozempic | Semaglutide | 141 | 38 |
| Trulicity | Dulaglutide | 136 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 134 | 19 |
| Eliquis | Apixaban | 133 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 42 |
| Bupropion Xl | Bupropion Hcl | 124 | 31 |
| Simvastatin | Simvastatin | 123 | 28 |
| Alprazolam | Alprazolam | 111 | 23 |
| Glipizide Er | Glipizide | 111 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 100 | 20 |
| Allopurinol | Allopurinol | 98 | 32 |
| Baclofen | Baclofen | 98 | 20 |
| Atenolol | Atenolol | 94 | 24 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 92 | 12 |
| Aripiprazole | Aripiprazole | 90 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 17 |
| Spironolactone | Spironolactone | 82 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 20 |
| Lorazepam | Lorazepam | 77 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 21 |
| Finasteride | Finasteride | 75 | 24 |
| Topiramate | Topiramate | 74 | 16 |
| Buspirone Hcl | Buspirone Hcl | 73 | 17 |
| Estradiol | Estradiol | 72 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 70 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 70 | 14 |
| Farxiga | Dapagliflozin Propanediol | 68 | 16 |
| Prednisone | Prednisone | 68 | 35 |
| Lamotrigine | Lamotrigine | 66 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 64 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 12 |
| Linzess | Linaclotide | 61 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 60 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 14 |
| Diazepam | Diazepam | 53 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 50 |
| Ondansetron Odt | Ondansetron | 53 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 19 |
| Lovastatin | Lovastatin | 50 | 11 |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Novolog Flexpen | Insulin Aspart | 50 | 14 |
| Nystatin | Nystatin | 50 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 19 |
| Xarelto | Rivaroxaban | 50 | 11 |
| Ezetimibe | Ezetimibe | 48 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | suppressed |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Rexulti | Brexpiprazole | 45 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 14 |
| Glimepiride | Glimepiride | 42 | 18 |
| Celecoxib | Celecoxib | 41 | 13 |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 39 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Naproxen | Naproxen | 36 | suppressed |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 11 |
| Colestipol Hcl | Colestipol Hcl | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 26 |
| Spiriva Handihaler | Tiotropium Bromide | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Nyamyc | Nystatin | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 11 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Cephalexin | Cephalexin | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,097.49 · 119 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ARISTADA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE, GEMTESA, Heplisav-B, JARDIANCE, LINZESS, LYBALVI, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Rybelsus, SLYND, SPRAVATO, Senza, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, UPLIZNA, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error